APG-115 for Chronic Myelomonocytic Leukemia

Seattle Cancer Care Alliance, Seattle, WA
Chronic Myelomonocytic Leukemia+5 More ConditionsAPG-115 - Drug
All Sexes

Study Summary

This trial is testing a new drug, APG-115, to see if it is safe and effective in treating patients with relapsed or refractory leukemia.

Eligible Conditions
  • Chronic Myelomonocytic Leukemia
  • Myelodysplastic Syndrome
  • Acute Myeloid Leukemia

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 1 & 2

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 28 days

28 days
Maximum Tolerated Dose

Trial Safety

Phase-Based Safety

1 of 3

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Approved for 5 Other Conditions
This treatment demonstrated efficacy for 5 other conditions.

Trial Design

2 Treatment Groups

APG-115 monotherapy
1 of 2
APG-115 + 5-azacitidine combination
1 of 2

Experimental Treatment

69 Total Participants · 2 Treatment Groups

Primary Treatment: APG-115 · No Placebo Group · Phase 1 & 2

APG-115 monotherapy
Experimental Group · 1 Intervention: APG-115 · Intervention Types: Drug
APG-115 + 5-azacitidine combinationExperimental Group · 2 Interventions: APG-115, 5-azacitidine · Intervention Types: Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 1
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 28 days

Who is running the clinical trial?

Ascentage Pharma Group Inc.Lead Sponsor
42 Previous Clinical Trials
3,098 Total Patients Enrolled
Yifan Zhai, MD, PhDStudy ChairAscentage Pharma Group Inc.
17 Previous Clinical Trials
1,202 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 0 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

How many centers are actively managing this research initiative?

"This medical trial is being conducted across 9 locations, such as the Duke University in Durham and the Texas Oncology - Baylor Charles A. Sammons Cancer Center located in Dallas, TX. There are also other sites like Banner MD Anderson Cancer Centre based in Gilbert." - Anonymous Online Contributor

Unverified Answer

Is enrollment in this experiment open to the public?

"Indeed, the details posted on clinicaltrials.gov verify that this investigation is actively recruiting participants. This study was initially publicised on December 4th 2020 and amended most recently on July 8th 2022; it requires 69 test subjects from 9 medical centres." - Anonymous Online Contributor

Unverified Answer

Are there any precedent studies that have used APG-115?

"APG-115 was first researched in 2006 at the Chinese University of Hong Kong-Prince of Wales Hospital. So far, 161 clinical trials have been completed and 174 are currently ongoing with a significant portion occurring in Durham, North Carolina." - Anonymous Online Contributor

Unverified Answer

What is the current enrollment rate of this clinical trial?

"To fulfil the requirements of this research project, 69 participants that meet set inclusion criteria must be recruited. Patients have access to trial sites such as Duke University in Durham and Texas Oncology - Baylor Charles A. Sammons Cancer Center in Dallas for their participation." - Anonymous Online Contributor

Unverified Answer

What maladies are typically addressed by the administration of APG-115?

"APG-115 is generally prescribed for malignant neoplasms, but has also been validated to treat 20-30% blasts, neutropenia and/or thrombocytopenia, anemia." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.